Pasithea Capex Per Share from 2010 to 2024

KTTAW Stock  USD 0.03  0.00  0.00%   
Pasithea Therapeutics Capex Per Share yearly trend continues to be fairly stable with very little volatility. Capex Per Share will likely drop to 0.000026 in 2024. During the period from 2010 to 2024, Pasithea Therapeutics Capex Per Share regression line of quarterly data had mean square error of  0.18 and geometric mean of  0.01. View All Fundamentals
 
Capex Per Share  
First Reported
2010-12-31
Previous Quarter
0.00002718
Current Value
0.000026
Quarterly Volatility
0.43334216
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 680.9 K, Other Operating Expenses of 9.9 M or Total Operating Expenses of 9.8 M, as well as many indicators such as Price To Sales Ratio of 36.39, Dividend Yield of 0.0 or PTB Ratio of 0.38. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Pasithea Therapeutics Correlation against competitors.

Latest Pasithea Therapeutics' Capex Per Share Growth Pattern

Below is the plot of the Capex Per Share of Pasithea Therapeutics Corp over the last few years. It is Pasithea Therapeutics' Capex Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pasithea Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Capex Per Share10 Years Trend
Slightly volatile
   Capex Per Share   
       Timeline  

Pasithea Capex Per Share Regression Statistics

Arithmetic Mean0.13
Geometric Mean0.01
Coefficient Of Variation338.81
Mean Deviation0.21
Median0.02
Standard Deviation0.43
Sample Variance0.19
Range1.6941
R-Value0.30
Mean Square Error0.18
R-Squared0.09
Significance0.28
Slope0.03
Total Sum of Squares2.63

Pasithea Capex Per Share History

2024 2.6E-5
2023 2.7E-5
2022 1.69

About Pasithea Therapeutics Financial Statements

Pasithea Therapeutics investors use historical fundamental indicators, such as Pasithea Therapeutics' Capex Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pasithea Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.